Unii-4U07F515lg

Base Information

• Chemical Name: Unii-4U07F515lg
• CAS No.: 496775-62-3
• Molecular Formula: C25H22N4O4·2(C2H7NO)
• Molecular Weight: 564.6394
• Mol file: 496775-62-3.mol

Synonyms:Eltrombopag;(1,1'-Biphenyl)-3-carboxylic acid, 3'-((2Z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazino)-2'-hydroxy-, compound with 2-aminoethanol (1:2);3'-((2Z)-2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)diazanyl)-2'-hydroxybiphenyl-3-carboxylic acid compound with 2-aminoethanol (1:2);Promacta;Revolade;SB 497115GR;SB-497115-GR;UNII-4U07F515LG;(1,1'-Biphenyl)-3-carboxylic acid, 3'-((2Z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazino)-2'-hydroxy, compound with 2-Aminoethanol (1:2);

Chemical Property of Unii-4U07F515lg

Chemical Property:

• PSA: 209.05000
• LogP: 3.12780
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C

Purity/Quality:

99% ,99.9%, ^*data from raw suppliers

EltrombopagOlamine ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Uses: Treatment of chemotherapy-induced thrombocytopenia and treatment of immune thrombocytopenic purpura.
• Clinical Use: Eltrombopag olamine, a thrombopoietin receptor (TpoR) agonist, was approved in late 2008 for the once-daily, oral short-term and long-term treatment of adult patients with previously treated chronic idiopathic thrombocytopenic purpura (ITP). It is the first small-molecule TpoR agonist and was launched in the U.S. for this indication in 2009 by GlaxoSmithKline (GSK). Because eltrombopag is a small molecule, the drug is administered orally and has a reduced potential for causing an immune system reaction versus alternative protein-based therapies. In 2010, eltrombopag was approved in Europe for the long-term treatment of adult patients with previously treated chronic ITP.